Skip to main content

Table 1 Patient characteristics

From: Application of prothrombin complex concentrate for reversal of direct oral anticoagulants in clinical practice: indications, patient characteristics and clinical outcomes compared to reversal of vitamin K antagonists

 

Total (n = 346)

DOAC (n = 74)

Vitamin K antagonist (n = 272)

p

Age, [median (IQR)]

78.0

(70–84)

77.0

(69–82)

79.0

(72–84)

0.064

Gender (male)

199

(57.5)

45

(60.8)

154

(56.6)

0.518

Comorbidities

 Hypertension

146

(42.2)

30

(40.5)

116

(42.6)

0.745

 Diabetes

63

(18.2)

10

(13.5)

53

(19.5)

0.238

 Peripheral arterial disease

26

(7.5)

6

(8.1)

20

(7.4)

0.827

 Hypertensive cardiopathy

75

(21.7)

17

(23.0)

58

(21.3)

0.760

 Coronary heart disease

91

(26.3)

14

(18.9)

77

(28.3)

0.104

 Valvular cardiopathy

75

(21.7)

15

(20.3)

60

(22.1)

0.741

 Chronic kidney disease

99

(28.6)

25

(33.8)

74

(27.2)

0.267

 Liver insufficiency

6

(1.7)

2

(2.7)

4

(1.5)

0.472

 COPD

21

(6.1)

6

(8.1)

15

(5.5)

0.407

 Venous thromboembolism

61

(17.6)

11

(14.9)

50

(18.4)

0.481

 Aortic disease

15

(4.3)

3

(4.1)

12

(4.4)

0.893

 Stroke

48

(13.9)

9

(12.2)

39

(14.3)

0.631

 Carcinoma

37

(10.7)

16

(21.6)

21

(7.7)

0.001

 Coagulopathy

13

(3.8)

1

(1.4)

12

(4.4)

0.220

  1. Abbreviation: DOAC direct oral anticoagulants, COPD chronic obstructive pulmonary disease